Joshua Matthew Rhett

Title
InstitutionMedical University of South Carolina
DepartmentPharmacology Allocation & Reserves
AddressP.O. Box MSC 509
HCC 702
Hollings Cancer Center - 86 Jonathan Lucas St.
Phone843-792-2277
Fax843-792-2475
vCardDownload vCard

    Collapse Biography 
    Collapse awards and honors
    2002 - PresMember of Sigma Xi
    2003 - 2004GAANN Fellow, Medical University of South Carolina
    2005 - 2007T32 Grantee in Cardiovascular Research, Medical University of South Carolina
    2008 - 2010South Carolina Space Grant Consortium Fellow, Medical University of South Carolina
    2009 - PresMember of American Heart Association
    2011Cover article in Molecular Biology of the Cell
    20111st place for oral presentation in the Postdoc-Resident-Fellow category, MUSC Student Research Day
    2012Cover article in Heart Rhythm
    2013Cover article in Trends in Cardiovascular Medicine
    20131st place for oral presentation in the Postdoc category, MUSC Dept of Surg Research Appreciation Day
    2014Featured article in Tissue Engineering Part B, Reviews
    2014 - PresSouth Carolina Translational Research Grantee

    Collapse Overview 
    Collapse overview
    My work is aimed at elucidating the role that connexin channels play in ATP signaling during injuries. We hypothesize that microvascular endothelial cells near an injury release ATP, and attract inflammatory cells to wounded tissue. Although inflammation is a necessary component of wound healing, inflammatory cells can cause tissue damage. Understanding the molecular mechanisms behind this process could lead to therapies directed at dampening the inflammatory response during wound resolution, and improve the foreign body response to implanted materials and tissues.
    Collapse keywords
    Wound Healing and the Foreign Body Response, Connexin Proteins and Cell-Cell Communication, Purinergic Signaling

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Khan I, Koide A, Zuberi M, Ketavarapu G, Denbaum E, Teng KW, Rhett JM, Spencer-Smith R, Hobbs GA, Camp ER, Koide S, O'Bryan JP. Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants. Cell Rep. 2022 02 08; 38(6):110322. PMID: 35139380.
      Citations:    
    2. Montgomery J, Richardson WJ, Marsh S, Rhett JM, Bustos F, Degen K, Ghatnekar GS, Grek CL, Jourdan LJ, Holmes JW, Gourdie RG. The connexin 43 carboxyl terminal mimetic peptide aCT1 prompts differentiation of a collagen scar matrix in humans resembling unwounded skin. FASEB J. 2021 08; 35(8):e21762. PMID: 34246197.
      Citations:    
    3. Rhett JM, Khan I, O'Bryan JP. Biology, pathology, and therapeutic targeting of RAS. Adv Cancer Res. 2020; 148:69-146. PMID: 32723567.
      Citations:    
    4. Zambrano JN, Eblen ST, Abt M, Rhett JM, Muise-Helmericks R, Yeh ES. HUNK Phosphorylates Rubicon to Support Autophagy. Int J Mol Sci. 2019 Nov 19; 20(22). PMID: 31752345.
      Citations:    
    5. Khan I, Rhett JM, O'Bryan JP. Therapeutic targeting of RAS: New hope for drugging the "undruggable". Biochim Biophys Acta Mol Cell Res. 2020 02; 1867(2):118570. PMID: 31678118.
      Citations:    
    6. Rhett JM, Yeh ES. The Potential for Connexin Hemichannels to Drive Breast Cancer Progression through Regulation of the Inflammatory Response. Int J Mol Sci. 2018 Mar 30; 19(4). PMID: 29601539.
      Citations:    
    7. Arbra CA, Nadig SN, Dennis SG, Pattanaik S, Bainbridge HA, Rhett JM, Fann SA, Atkinson C, Yost MJ. Microdissection of Primary Renal Tissue Segments and Incorporation with Novel Scaffold-free Construct Technology. J Vis Exp. 2018 03 27; (133). PMID: 29658916.
      Citations:    
    8. Rhett JM, Calder BW, Fann SA, Bainbridge H, Gourdie RG, Yost MJ. Mechanism of action of the anti-inflammatory connexin43 mimetic peptide JM2. Am J Physiol Cell Physiol. 2017 Sep 01; 313(3):C314-C326. PMID: 28701358.
      Citations:    
    9. Grek CL, Rhett JM, Bruce JS, Ghatnekar GS, Yeh ES. Connexin 43, breast cancer tumor suppressor: Missed connections? Cancer Lett. 2016 Apr 28; 374(1):117-126. PMID: 26884256.
      Citations:    
    10. Rhett JM, Wang H, Bainbridge H, Song L, Yost MJ. Connexin-Based Therapeutics and Tissue Engineering Approaches to the Amelioration of Chronic Pancreatitis and Type I Diabetes: Construction and Characterization of a Novel Prevascularized Bioartificial Pancreas. J Diabetes Res. 2016; 2016:7262680. PMID: 26788521.
      Citations:    
    11. Grek CL, Rhett JM, Bruce JS, Abt MA, Ghatnekar GS, Yeh ES. Targeting connexin 43 with a-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1. BMC Cancer. 2015 Apr 03; 15:296. PMID: 25881004.
      Citations:    
    12. Calder BW, Matthew Rhett J, Bainbridge H, Fann SA, Gourdie RG, Yost MJ. Inhibition of connexin 43 hemichannel-mediated ATP release attenuates early inflammation during the foreign body response. Tissue Eng Part A. 2015 Jun; 21(11-12):1752-62. PMID: 25760687.
      Citations:    
    13. Grek CL, Rhett JM, Ghatnekar GS. Cardiac to cancer: connecting connexins to clinical opportunity. FEBS Lett. 2014 Apr 17; 588(8):1349-64. PMID: 24607540.
      Citations:    
    14. Rhett JM, Fann SA, Yost MJ. Purinergic signaling in early inflammatory events of the foreign body response: modulating extracellular ATP as an enabling technology for engineered implants and tissues. Tissue Eng Part B Rev. 2014 Oct; 20(5):392-402. PMID: 24279914.
      Citations:    
    15. Rhett JM, Veeraraghavan R, Poelzing S, Gourdie RG. The perinexus: sign-post on the path to a new model of cardiac conduction? Trends Cardiovasc Med. 2013 Aug; 23(6):222-8. PMID: 23490883.
      Citations:    
    16. Rhett JM, Ongstad EL, Jourdan J, Gourdie RG. Cx43 associates with Na(v)1.5 in the cardiomyocyte perinexus. J Membr Biol. 2012 Jul; 245(7):411-22. PMID: 22811280.
      Citations:    
    17. Palatinus JA, Rhett JM, Gourdie RG. The connexin43 carboxyl terminus and cardiac gap junction organization. Biochim Biophys Acta. 2012 Aug; 1818(8):1831-43. PMID: 21856279.
      Citations:    
    18. Palatinus JA, Rhett JM, Gourdie RG. Enhanced PKCe mediated phosphorylation of connexin43 at serine 368 by a carboxyl-terminal mimetic peptide is dependent on injury. Channels (Austin). 2011 May-Jun; 5(3):236-40. PMID: 21532342.
      Citations:    
    19. Rhett JM, Jourdan J, Gourdie RG. Connexin 43 connexon to gap junction transition is regulated by zonula occludens-1. Mol Biol Cell. 2011 May; 22(9):1516-28. PMID: 21411628.
      Citations:    
    20. Palatinus JA, Rhett JM, Gourdie RG. Translational lessons from scarless healing of cutaneous wounds and regenerative repair of the myocardium. J Mol Cell Cardiol. 2010 Mar; 48(3):550-7. PMID: 19560469.
      Citations:    
    21. Rhett JM, Ghatnekar GS, Palatinus JA, O'Quinn M, Yost MJ, Gourdie RG. Novel therapies for scar reduction and regenerative healing of skin wounds. Trends Biotechnol. 2008 Apr; 26(4):173-80. PMID: 18295916.
      Citations:    
    22. Choi, E., Knight, J.D., Malatanos, M.D., Rhett, J.M., Walters, M.J., Dunn, S.P., Beam, C.F. Preparation of 4,5-Dihydronaphth[2,1-c]isoxazoles from Dilithiated 2-Tetralone Oxime and Select Esters. Synthetic Communications. 2008; (38):713-22.
    23. Gourdie RG, Ghatnekar GS, O'Quinn M, Rhett MJ, Barker RJ, Zhu C, Jourdan J, Hunter AW. The unstoppable connexin43 carboxyl-terminus: new roles in gap junction organization and wound healing. Ann N Y Acad Sci. 2006 Oct; 1080:49-62. PMID: 17132774.
      Citations:    
    24. Virella G, Thorpe SR, Alderson NL, Derrick MB, Chassereau C, Rhett JM, Lopes-Virella MF. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J Lipid Res. 2004 Oct; 45(10):1859-67. PMID: 15258197.
      Citations:    
    25. Dillon, R.T., Wethington, A.R., Rhett, J.M., Smith, T.P. Populations of the European freshwater pulmonate Physa acuta are not reproductively isolated from American Physa heterostropha or Physa integra. Invertebrate Biology. 2002; (121):226-234.
    26. Orr RK, Hoehn JL, Col NF. The learning curve for sentinel node biopsy in breast cancer: practical considerations. Arch Surg. 1999 Jul; 134(7):764-7. PMID: 21978964.
      Citations:    
    27. Hengst W, Mosler D. [Critical evaluation of liver function tests, using 131 I bromsulphan and bromphthaline]. Fortschr Geb Rontgenstr Nuklearmed. 1973 Mar; 118(3):330-5. PMID: 4691620.
      Citations:    
    Rhett's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (156)
    Explore
    _
    Co-Authors (14)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _